Lymphoma, Non-Hodgkin × Cyclophosphamide × 90 days × Clear all
NCT03849651 2026-06-03

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
69 enrolled 17 charts
NCT00544115 2026-06-02

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT02727803 2026-05-22

Personalized NK Cell Therapy in CBT

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
NCT01962636 2026-05-20

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
200 enrolled
NCT00641381 2026-05-04

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

City of Hope Medical Center

Phase 1 Completed
25 enrolled
NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled 15 charts
NCT07166419 2026-04-15

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
24 enrolled
NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
35 enrolled 19 charts